Association Between PSA Screening, Prostate Cancer Mortality Among Non-Hispanic Black, Non-Hispanic White Veterans

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, AUGUST 4, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2022.2970?guestAccessKey=06430554-cf5a-42e4-b950-adbebba956fa&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=080422

 

About The Study: In this study of 45,800 U.S. veterans, prostate-specific antigen (PSA) screening was associated with reduced risk of prostate cancer–specific mortality (PCSM) among non-Hispanic Black men and non-Hispanic white men. Compared with less frequent screening, annual screening was associated with decreased risk of PCSM among Black men but not among white men, suggesting that annual screening may be particularly important for Black men.

Authors: Brent S. Rose, M.D., of the University of California, San Diego in La Jolla, is the corresponding author.

 

(doi:10.1001/jamaoncol.2022.2970)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.